Bacteriallysates (BL) had been used as immunomodulators in asthma and allergic rhinitis. No data is available for bacterial suspensions (BS) and ocular allergy. Previously, we observed that peripheral blood mononuclear cells (PBMC) from healthy subjects stimulated with BS increase the percentage of CD19 +IL-10 + cells in vitro. This finding is relevant since it has been reported that patients with ocular allergy had low expression of IL-10 in B circulating cells. Thus, the aim of this work was to evaluate the percentage of IL-10+ producing B cells in patients with allergic conjunctivitis treated with a commercial BS formulation (IPI). The clinical study was approved by the local Ethical board, and patients included were treated according to manufacturer instructions. After 3 months of treatment with BS, patients increased 9.8 times the percentage of circulating CD19+CD10+ cells (p=0.01) and decreased 3 times the ocular severity score when compared with the beginning of treatment (p=0.008). Our results suggest that adding BS to the standardized ophthalmological treatment could be a new therapeutic tool to modify pathological immune response seen in ocular allergy by inducing positive changes in the percentage of circulating IL-10+ B cells and favoring a better clinical outcome in patients with allergic conjunctivitis.